AzTrials
AzTrials

AgingBIOANCIENT_EXNCT07723339

BIOANCIENT_EX: Effects of a Physical Exercise Program in Centenarians of the BIOANCIENT Cohort: A Randomized Clinical Trial.

A study testing Exercise in people with Aging and Cellular Senescence, run by Fundacion Miguel Servet at 1 site in Spain.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

This study aims to evaluate the effects of a home intervention of individualized multicomponent physical exercise program (including strength, balance, flexibility, and mobility training) on functional health, physical capacity, and biological markers in centenarians. Read more about this study

Who is it for?
Ages 100 years and older
Conditions the study is for
Aging, Cellular Senescence, Biomarkers / Blood
What is being tested?
Exercise
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteSpain
Study dates
13 Aug 2026to Dec 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 100 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Who may be able to join

  • Individuals aged ≥ 100 years;
  • Residents of Navarre.;
  • Barthel Index score ≥ 60, capable of standing and performing transfers independently or with minimal assistance;
  • Stable clinical condition;
  • Ability to follow simple instructions;
  • Signed informed consent (by the participant or legal representative).

Who cannot join

  • Acute illness or unstable chronic condition, clinical decompensation within the last month: hemodynamic instability, acute pathology, hospitalization;
  • Severe cardiovascular or respiratory pathology that contraindicates exercise;
  • Severe cognitive impairment preventing participation;
  • Recent fracture or major surgery (< 3 months).
  • Individuals in an end-of-life situation, defined as a clinical state of irreversible decline with a life expectancy of less than weeks or months, according to medical criteria.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Spain1 site
  • Navarrabiomed

    Pamplona, Navarre, 31001

Other trials in Spain

About this study

This study aims to evaluate the effects of a home intervention of individualized multicomponent physical exercise program (including strength, balance, flexibility, and mobility training) on functional health, physical capacity, and biological markers in centenarians. The intervention includes periodic monitoring and individualized exercise progression every three weeks.

Read the detailed description

The BIOANCIENT_EX study is a randomized clinical trial designed to assess the impact of an individualized structured physical exercise program in an elderly population. The intervention includes exercises designed to enhance the functional capacity and independence of centenarians. The strength training aims to target large muscle groups, alongside static and dynamic balance training, joint mobility, and aerobic capacity exercises. The control group will maintain their habitual routine.

Participants are continuously monitored through regular follow-up using phone calls, video calls, or home visits when necessary. It is recommended that exercise sessions be performed in the company of a family member or caregiver. Additionally, audiovisual materials will be made available to facilitate the execution of the exercises. Exercise intensity and complexity are adjusted every three weeks based on participant performance and safety.

Being tested
Exercise
Keywords
Centenarians, Healthy aging, Senescence, Longevity, Personalized medicine, Preventive medicine, Omics technologies (genomics, proteomics, metabolomics), Artificial intelligence in healthcare, Exercise
Medical subject headings
Motor Activity, Frailty

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ExerciseOther

    Also called Group 1

    Participants in the intervention group will take part in an individualized multicomponent physical training program including exercises targeting strength, balance, and aerobic capacity, adapted to older adults and conducted following established safety guidelines.

Study groups in NCT07723339
Study groupRoleWhat they receive
ControlNo interventionParticipants assigned to the control group will receive usual care and will not undergo any specific intervention related to individualized multicomponent exerceise. They will continue doing their daily routine.
ExerciseExperimentalParticipants in this group will take part in a individualized multicomponent physical training program including exercises targeting strength, balance, and aerobic capacity, adapted to centenarians and conducted following established safety guidelines.
Receives: Other: Exercise

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Physical function assessed by Short Physical Performance Battery (SPPB)

    Physical Function: Assessed using the Short Physical Performance Battery (SPPB), which combines balance, gait velocity, and leg strength as a single score on a 0 (worst) to 12 (best scale).

    Measured: Baseline and 12-week follow-up

Secondary outcomes (21)
  1. Health-related quality of life index score assessed by the EQ-5D-5L

    The EQ VAS ranges from 0 (worst imaginable health) to 100 (best imaginable health). Higher scores indicate better health status. The EQ-5D-5L descriptive system is a standardized instrument for measuring health-related quality of life. It comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels of severity: no problems, slight problems, moderate problems, severe problems, and extreme problems. This descriptive system is converted into a single utility index score using a country-specific value set. Index scores typically range from less than 0 (where 0 represents death and negative values represent states worse than death) to 1 (representing perfect health). Higher scores indicate better health states.

    Measured: Baseline and 12-week follow-up

  2. Patient self-rated health status assessed by the EQ-5D-5L VAS

    The EQ Visual Analogue Scale (EQ VAS) is a component of the EQ-5D-5L questionnaire that records the respondent's self-rated health on a vertical visual analogue scale. Scores range from 0 to 100, where 0 represents 'the worst health you can imagine' and 100 represents 'the best health you can imagine'. Higher scores indicate a better self-perceived health status.

    Measured: Baseline and 12-week follow-up

  3. Functional status measured with Barthel Index

    Barthel Index of independence during activities of daily living (ADLs) ranges from 0 (severe functional dependence) to 100 (functional independence).

    Measured: Baseline and 12-week follow-up

  4. Cognitive Function assessed with Mini Mental State Examination (MMSE)

    Cognitive Function assessed with Mini-Mental State Examination (MMSE) is a 30-point tool designed to assess global cognitive function and screen for cognitive impairment, particularly in older adults. It evaluates several core areas of cognitive functioning, with higher scores indicating better cognitive performance, i.e. 30 (best) and 0 (worst).

    The 11 tasks in the MMSE are generally categorized into the following areas of cognitive functioning: Orientation (10 points), Registration (3 points), Attention and Calculation (5 points); Recall (3 points): .Language and Praxis (9 points).

    Measured: Baseline and 12-week follow-up

  5. Hand Grip Strength

    Muscle Strength assessed by handgrip strength using a dynamometer (Takey Physical Fitness Test) measured in kilograms. The minimum recorded measurement is 5 kg and the maximum is 100 kg. Grip strength is a powerful biomarker of aging and overall muscle strength. Low handgrip strength is associated with increased risks of cardiovascular disease, stroke, type 2 diabetes, and premature mortality.

    Measured: Baseline and 12-week follow-up

  6. Lower Limb Muscle Strength

    Lower Limb Muscle Strength. Isometric lower limb muscle strength assessed using a Hoggan dynamometer. Knee extensor strength and hip flexor strength will be measured with participants in a standardized seated position, starting with the knee flexed (90º). Force will be recorded in kilograms (kg). Higher values indicate greater muscle strength.

    Measured: Baseline and 12-week follow-up

  7. Cognitive Function (Clock Drawing Test)

    Cognitive function assessed using the Clock Drawing Test (CDT), in which participants are asked to draw a clock showing a specified time. The test evaluates executive function, visuospatial ability, and planning. Performance will be scored using a standardized scoring system, with higher scores indicating better cognitive performance. Results range from 0 (worst) to 10 (best).

    Measured: Baseline and 12-week follow-up

  8. Nutritional Status assessed using the Mini Nutritional Assessment - Short Form (MNA-SF)

    Nutritional Status assessed using the Mini Nutritional Assessment - Short Form (MNA-SF), a rapid, validated 6-item screening tool designed to identify older adults (aged 65+) who are malnourished or at risk of malnutrition. It is widely used in hospitals, nursing homes, and community settings to initiate early nutritional interventions. Scoring from 14 points (better) and 0 points (worse):12-14 points: Normal nutritional status; 8-11 points: At risk of malnutrition and; 0-7 points: Malnourished.

    Measured: Baseline and 12-week follow-up

  9. Sarcopenia Risk (SARC-F questionnaire)

    Risk of sarcopenia assessed using the SARC-F questionnaire, a five-item self-reported screening tool evaluating strength, assistance in walking, rising from a chair, climbing stairs, and falls. Total scores range from 0 to 10, with higher scores indicating greater risk of sarcopenia and functional decline.

    Measured: Baseline and 12-week follow-up

  10. Depressive Symptoms (Geriatric Depression Scale - GDS-15)

    Depressive symptoms assessed using the Geriatric Depression Scale (GDS-15), a 15-item self-reported questionnaire designed to screen for depression in older adults. Scores range from 0 to 15, with higher scores indicating more severe depressive symptoms. Scores of 0-4 are considered normal, 5-9 suggest mild depression, and 10-15 indicate moderate to severe depression.

    Measured: Baseline and 12-week follow-up

  11. Mobility and Functional Performance (Timed Up and Go Test - TUG)

    Mobility and functional performance assessed using the Timed Up and Go (TUG) test. Participants are instructed to stand up from a standard chair, walk a distance of 3 meters, turn around, walk back to the chair, and sit down. The total time to complete the task is recorded in seconds. Lower times indicate better mobility and functional performance.

    Times greater than or equal to 12 seconds are commonly associated with increased risk of falls in older adults.

    Measured: Baseline and 12-week follow-up

  12. Bioimpedance Analysis (BIVA - Bioelectrical Impedance Vector Analysis)

    Bioimpedance Analysis (BIVA - Bioelectrical Impedance Vector Analysis): Whole-body bioelectrical impedance vector analysis (BIVA) assessed using a phase-sensitive bioimpedance device (e.g., BIVA Pro). Raw bioelectrical parameters including resistance (R, ohms) and reactance (Xc, ohms) will be measured at 50 kHz and normalized by height (R/H, Xc/H).

    BIVA provides a qualitative and semi-quantitative assessment of body composition, including hydration status and body cell mass, without relying on predictive equations. Vector displacement patterns will be interpreted as follows:

    Vector shortening (↓R/H, ↓Xc/H): fluid overload or increased hydration Vector lengthening (↑R/H, ↑Xc/H): dehydration or reduced fluid content Increased phase angle: better cellular integrity and nutritional status Decreased phase angle:

    impaired cellular health or frailty.

    Measured: Baseline and 12-week follow-up

  13. Proteomic Biomarkers

    Proteomic biomarkers assessed through the identification and quantification of circulating proteins associated with aging and frailty using high-throughput proteomic techniques. Protein expression levels will be measured in biological samples (e.g., plasma or serum), and relative or absolute concentrations will be analyzed.

    Measured: Baseline (single assessment)

  14. Falls (Number of falls over the past 12 months)

    Total number of unintentional falls experienced by the participant during the 12 months prior to the assessment. A fall is defined as an unexpected event in which the participant comes to rest on the ground, floor, or lower level. Data will be collected via self-report calendar.

    Measured: Baseline and 12-week follow-up

  15. Fear of Falling

    Assessment of the participant's fear of falling, categorized as a dichotomous outcome (Yes or No). Participants are asked the single standard question: "Are you afraid of falling?". A response of "Yes" indicates the presence of fear, while "No" indicates its absence.

    Measured: Baseline and 12-week follow-up

  16. Pain Intensity

    Pain intensity will be assessed using a standard Visual Analog Scale (VAS). The scale consists of a 10 cm horizontal line, where the left endpoint (0) represents "no pain" and the right endpoint (10) represents "worst imaginable pain". Participants mark the point on the line that best represents their current pain level. Higher scores indicate greater pain severity.

    Measured: Baseline and 12-week follow-up

  17. Polypharmacy

    Polypharmacy assessed as the concurrent use of multiple medications. The total number of regularly prescribed medications will be recorded for each participant. Polypharmacy will be defined as the use of five or more medications (≥5). The outcome will be analyzed both as a continuous variable (number of medications) and as a categorical variable (presence vs absence of polypharmacy). Higher values indicate greater medication burden.

    Prior and Concomitant Medication History; Baseline assessment of chronic pharmacological exposure. Participants report lifetime use (lasting >1 year) of 27 key drug classes (Yes/No), including cardiovascular, endocrine, respiratory, analgesic, anti-infective, neuropsychiatric, gastrointestinal, bone, and immune therapies. Long-term historical medications are also captured via open text. Reported as counts and percentages.

    Measured: Baseline and 12-week follow-up

  18. Comorbidity Burden

    Comorbidity burden assessed using the Cumulative Illness Rating Scale for Geriatrics (CIRS-G), which evaluates the severity of chronic medical conditions across 14 organ systems. Each system is rated on a 5-point scale (0 = no problem to 4 = extremely severe impairment). The total score ranges from 0 to 56, with higher scores indicating greater comorbidity burden.

    Measured: Baseline

  19. Comorbidity Profile and Disease Burden via ICD-10 Classification

    Evaluation of participant medical history and current health status classified according to the International Classification of Diseases, 10th Revision (ICD-10). Diagnoses will be extracted from electronic medical records or clinical interviews and mapped to their corresponding ICD-10 codes. The analysis will focus on the total number of coexisting chronic conditions per participant (disease burden) and the prevalence of major ICD-10 diagnostic chapters (e.g., cardiovascular, metabolic, musculoskeletal diseases).

    Measured: Baseline

  20. Plasma RNA sequencing profile

    Assessment of the RNA profile isolated from total plasma samples using next-generation sequencing (NGS) to evaluate changes over time.

    Measured: Baseline and 12-week follow-up

  21. Extracellular vesicle RNA sequencing profile

    Assessment of the RNA profile isolated from purified extracellular vesicles using next-generation sequencing (NGS) to evaluate changes over time.

    Measured: Baseline and 12-week follow-up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Jul 2026
  2. Study start13 Aug 2026
  3. Primary completionDec 2027 (estimated)
  4. Study completionDec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
Randomized Controlled Trial (RCT)
Masking
None (open label)
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07723339
Sponsor's protocol ID
BIOANCIENT_EX
Acronym
BIOANCIENT_EX
Status last verified
Aug 2026
First submitted
16 Jul 2026
Last updated
1 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Exercise in people with Aging and Cellular Senescence, run by Fundacion Miguel Servet at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 1 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Physical function assessed by Short Physical Performance Battery (SPPB) (time frame: Baseline and 12-week follow-up). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Sep 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
BIOANCIENT_EX Clinical Trial NCT07723339 | AzTrials